Valuation: Tsubota Laboratory Incorporated

Market Cap 5.91B 37.37M 33.36M 30.7M 27.86M 52.8M 3.5B 54.11M 367M 146M 1.88B 140M 137M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 5.01B 31.67M 28.27M 26.01M 23.61M 44.74M 2.97B 45.86M 311M 124M 1.59B 119M 116M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
08-12 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
06-01 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
06-01 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/05/25 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/02/25 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/11/24 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/12/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/09/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
1 day+3.62%
1 week-5.76%
Current month-5.76%
1 month-10.55%
3 months-11.92%
6 months-22.90%
Current year-32.65%
1 week 216
Extreme 216
238
1 month 216
Extreme 216
265
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 66 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Others

Founder

63,000 0.2465%
15/11/24 Others

Founder

420,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
+3.62%-5.76%-30.40%-51.38% 36M
+2.24%+5.83%+58.47%+65.65% 66.7B
+4.66%+8.90%+14.57%+85.41% 56.88B
-0.60%+1.73%+23.48%+94.40% 56.53B
+2.80%+16.04%+27.34%+121.16% 46.49B
+2.55%+8.06%+31.08%+45.52% 44.8B
+3.13%+5.82%+217.44%+894.66% 41.59B
-0.47%+9.60%+27.53%+52.88% 35.35B
+3.80%-1.00%+95.20%+66.79% 33.29B
+0.69%+5.62%-39.84%+392.95% 25.1B
Average +2.32%+2.05%+42.49%+176.80% 40.68B
Weighted average by Cap. +2.27%+3.96%+51.39%+180.46%

Financials

2025 2026
Net sales 1.36B 8.59M 7.66M 7.05M 6.4M 12.13M 805M 12.43M 84.36M 33.62M 431M 32.23M 31.54M 200M 1.27M 1.13M 1.04M 943K 1.79M 119M 1.83M 12.43M 4.96M 63.5M 4.75M 4.65M
Net income 205M 1.3M 1.16M 1.07M 967K 1.83M 122M 1.88M 12.74M 5.08M 65.09M 4.87M 4.76M -761M -4.81M -4.3M -3.95M -3.59M -6.8M -451M -6.97M -47.31M -18.86M -242M -18.07M -17.69M
Net Debt -1.45B -9.16M -8.18M -7.52M -6.83M -12.94M -859M -13.26M -90.02M -35.88M -460M -34.39M -33.65M -901M -5.7M -5.09M -4.68M -4.25M -8.05M -534M -8.25M -56.01M -22.33M -286M -21.4M -20.94M
Projected Income Statement - Annual - Tsubota Laboratory Incorporated
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
09/11/26 JP¥229.00 +3.62% 15,200
06/11/26 JP¥221.00 -5.56% 49,900
05/11/26 JP¥234.00 +1.74% 31,100
04/11/26 JP¥230.00 -3.36% 36,800
02/11/26 JP¥238.00 -2.06% 11,800
  1. Stock Market
  2. Stocks
  3. 4890 Stock